Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — H1 FY2019 Earnings Presentation
19 slides from Dr. Lal Pathlabs's earnings presentation, Nov 6, 2018
Slide 1: Cover letter to stock exchanges on results presentation
November 6, 2018 The National Stock Exchange of India Limited The Bombay Stock Exchange Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Bandra (E) Dalal Street, Mumbai - 400051 Mumbai - 400001 Subject: Investors Presentation on Unaudited Financial Results (Standalone and Consol
Slide 2: Q2 & H1 FY19 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q2 & H1 FY19 Results Presentation November 06, 2018
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Q2 FY19 Snapshot
Q2 FY19 Snapshot 14.1% Revenues INR 3,175 mn Samples Processed ~11.1 mn 12.1% Normalised INR 905 mn Patients Tested ~4.8 mn EBITDA 12.8% PAT INR 574 mn Total Employees* ~4,316 *As on March 31, 2018, 3
Slide 5: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Performance Highlights 3 Financial Table 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Shareholding 10 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at
Slide 6: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs 193 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi and Regional Ref lab at diagnostic services Kolkata), 2,153 Patient Service Centers (PSCs) and 5,624 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1110 t
Slide 7: Key Performance Highlights
Key Performance Highlights Trend of volume improvement continues in Q2. Patient volumes and tests per patient show healthy increase During Q2 FY19: • Revenues showed 14.1% improvement to Rs. 3175 million in Q2 FY19, on the back of 18.8% gains in volumes • Number of patients tested was at 4.8 million
Slide 8: Financial Table
Financial Table Particulars (Rs. mn) Q2 FY19 Q2 FY18 Growth % H1 FY19 H1 FY18 Growth % Total Revenue 3,175 2,781 14.1% 6,098 5,274 15.6% Total Expenditure 2,307 2,003 4,479 3,840 EBITDA 868 779 11.5% 1,618 1,434 12.9% Adj for RSU, and stock based comp. & CSR 37 29 80 54 Cost Normalised operating EBI
Slide 9: Financial Highlights
Financial Highlights Revenues All figures in Rs. mn Q2 delivered 14.1% increase in revenues at Rs. 3,175 million. Drivers of performance were: • Continued traction in patient volumes at 6,098 18.8% 3,175 5,274 2,781 • Stable tests per patient at 2.34 vs. 2.28 Realisation per patient declined fro
Slide 10: Financial Highlights
Financial Highlights PBT All figures in Rs. mn 881 Q2 PBT came in at Rs. 881 million vs. 778 1,635 1,438 Rs. 778 million last year PBT margin stood at 27.8% from 28% last year H1 PBT stood at Rs. 1,635 million with margins at 26.8% Q2 FY18 Q2 FY19 H1 FY18 H1 FY19 PAT 574 Q2 PAT stood at Rs.
Slide 11: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs 2,153 No. of PUPs 1,759 189 193 1,559 164 172 1,340 5,668 5,624 4,967 5,021 FY15 FY16 FY17 FY18 FY15 FY16 FY17 FY18 FY15 FY16 FY17 FY18 No. of patients (mn) No. of samples (mn) 15.2 13.3 34.7 12.0 29.3 9.9 26.3 8.9 21.7 20.9 FY15 FY16 FY1
Slide 12: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; "The reported performance gives me comfort that we are headed in the right direction especially with regards to growth momentum and sharp focus on improving efficiencies in the system.
Slide 13: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services Initiatives to improve brand con
Slide 14: Corporate Overview
Corporate Overview • DLPL Strategy for future growth • Experienced Management team 13
Slide 15: DLPL Strategy for future growth
DLPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 14
Slide 16: DLPL Strategy for future growth
DLPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Lif
Slide 17: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Chairman and Managing Director Whole-time Director and Chief Whole-time Director Executive Officer Ved Prakash Goel Bharath Uppiliappan Shankha Banerjee Chief Financial Officer Chief Operating Officer Chief Gro
Slide 18: Shareholding as of 30th September, 2018
Shareholding as of 30th September, 2018 57.4% 7.0% Promoter and Promoter Mutual Group Funds 17.0% 18.6% FII Others 17
Slide 19: Contact us
Contact us About Dr Lal PathLabs Limited (DLPL) For further information please contact: Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. Ved Goel / Rajat Kalra It has an integrated nationwide network, where patients Dr. Lal PathLabs Limited and heal